These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23447426)

  • 1. A cup of coffee a day keeps dyskinesia away?
    Jenner P
    Mov Disord; 2013 Mar; 28(3):265-7. PubMed ID: 23447426
    [No Abstract]   [Full Text] [Related]  

  • 2. Caffeine consumption and risk of dyskinesia in CALM-PD.
    Wills AM; Eberly S; Tennis M; Lang AE; Messing S; Togasaki D; Tanner CM; Kamp C; Chen JF; Oakes D; McDermott MP; Schwarzschild MA;
    Mov Disord; 2013 Mar; 28(3):380-3. PubMed ID: 23339054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Nicoletti A; Zappia M;
    Mov Disord; 2015 Nov; 30(13):1854-6. PubMed ID: 26769461
    [No Abstract]   [Full Text] [Related]  

  • 4. Adenosine A2A receptor antagonists in Parkinson's disease: still in the running.
    Antonini A; Poewe W
    Lancet Neurol; 2014 Aug; 13(8):748-9. PubMed ID: 25008550
    [No Abstract]   [Full Text] [Related]  

  • 5. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pramipexole on the onset of levodopa-related dyskinesias.
    Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
    Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
    Xiao D; Cassin JJ; Healy B; Burdett TC; Chen JF; Fredholm BB; Schwarzschild MA
    Brain Res; 2011 Jan; 1367():310-8. PubMed ID: 20828543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Huang YX; Luo WF; Li D; Hu WD; Liu CF
    Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
    Brodsky MA; Park BS; Nutt JG
    Arch Neurol; 2010 Jan; 67(1):27-32. PubMed ID: 20065126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Kordower JH
    Mov Disord; 2017 Apr; 32(4):483-484. PubMed ID: 28425143
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Istradefylline (Nourianz) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
    [No Abstract]   [Full Text] [Related]  

  • 16. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    Olanow CW; Stocchi F
    Eur J Neurol; 2000 May; 7 Suppl 1():3-8. PubMed ID: 11054152
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias.
    Wagle-Shukla A; Angel MJ; Zadikoff C; Enjati M; Gunraj C; Lang AE; Chen R
    Neurology; 2007 Feb; 68(9):704-5. PubMed ID: 17325284
    [No Abstract]   [Full Text] [Related]  

  • 19. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical strategies to prevent and delay motor complications.
    Barone P
    Neurology; 2003 Sep; 61(6 Suppl 3):S12-6. PubMed ID: 14504375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.